Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
March 28, 2013
- AnGes Licenses Nucleic Acid Drug for Diseases Causing Lower Back Pain to Nippon Zoki in Japan
March 28, 2013
- Takeda, Novartis Rank 1st in Total Average Score with Favorable Impression on Quality of Development: IAL Survey
March 28, 2013
- Concurrent-Use Indications Approved for Trazenta: NBI, Eli Lilly Japan
March 27, 2013
- ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
- New Parkinson’s Disease Treatment Nouriast Approved: Kyowa Kirin
March 27, 2013
- FD Treatment Acofide Approved: Zeria, Astellas
March 27, 2013
- Otsuka Receives Approval for DPP-4 Inhibitor Onglyza, to Transfer Marketing Rights to Kyowa Kirin
March 27, 2013
- Takeda Announces Full Cancellation of Correction Notice Based on Transfer Pricing Tax System; 15.2 Billion Yen Refund Expected
March 27, 2013
- Marc Dunoyer Steps Down as Chairman of GSK K.K.
March 26, 2013
- Terumo Launches Cancer Pain Treatment Methapain
March 26, 2013
- Takeda Files NDA for Malignant Lymphoma Treatment Brentuximab Vedotin in Japan
March 26, 2013
- JAK Inhibitor Xeljanz Approved for RA: Pfizer Japan
March 26, 2013
- Regtect Approved for Supporting Maintenance of Abstinence in Patients with Alcohol Dependence: Nippon Shinyaku
March 26, 2013
- Daiichi Sankyo Aims for Approval of Enbrel Biosimilar in FY2016: President Nakayama
March 26, 2013
- Daiichi Sankyo’s Osteoporosis Treatment Pralia Approved
March 26, 2013
- New Settai Rules Halfway to Establishment; Some in Industry Want Further Rules as Well
March 26, 2013
- Astellas Ties Up with Tokyo Tech and Nagasaki University to Research Anti-Dengue Virus Treatment
March 25, 2013
- Daiichi Sankyo Mulls Biz Platform after Olmesartan LOE: New 5 Year Plan
March 25, 2013
- Takeda Returns Global Rights to NPS Pharmaceuticals for Preotact and Revestive
March 25, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…